<DOC>
	<DOCNO>NCT00125944</DOCNO>
	<brief_summary>The objective ass safety bivalent vaccine two new 6:2 influenza virus reassortants healthy adult prior release trivalent vaccine ( FluMist ) containing .</brief_summary>
	<brief_title>Study Evaluate Safety Bivalent Vaccine New 6:2 Influenza Virus Reassortants Healthy Adults</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<criteria>Males female , 18 49 year age ( yet reach 50th birthday ) time study vaccination Healthy medical history health assessment Sexually active female , unless surgically sterile least 1 year postmenopausal , must use effective method avoid pregnancy ( include oral , implanted , injectable , transdermal contraceptive , intrauterine device [ IUD ] , female condom , diaphragm spermicide , cervical cap , abstinence , use condom sexual partner sterile sexual partner ) least 30 day prior study vaccination , must agree continue use precaution least 90 day study vaccination ; volunteer must also negative serum urine pregnancy test within 14 day prior study vaccination ( screen study vaccination occur day ) day study vaccination prior randomization Sexually active male , unless surgically sterile , must use effective method birth control ( condom abstinence ) must agree continue use precaution least 30 day study vaccination Available telephone Written inform consent ( Health Insurance Portability Accountability Act [ HIPAA ] authorization applicable ) obtain participant Ability understand comply requirement protocol , judge investigator Ability complete followup period 180 day study vaccination , require protocol History hypersensitivity component vaccine , include egg egg protein History hypersensitivity gentamicin Any condition inactivate influenza vaccine indicate , include chronic disorder pulmonary cardiovascular system ( e.g. , asthma ) ; chronic metabolic disease ( e.g. , diabetes mellitus ) ; renal dysfunction ; hemoglobinopathy require regular medical followup hospitalization precede year . Acute febrile ( &gt; 100.0°F oral equivalent ) and/or clinically significant respiratory illness ( e.g. , cough sore throat ) within 14 day prior randomization Any known immunosuppressive condition immune deficiency disease , include HIV infection , ongoing immunosuppressive therapy History GuillainBarré syndrome Household contact immunocompromised ( participant also avoid close contact immunocompromised individual least 21 day post study vaccination ) Receipt investigational agent within 30 day prior enrollment , expect receipt 180 day study vaccination ( use license agent indication list package insert permit ) Chronic regular use antipyretic analgesic medication daily every day basis . Note : A daily dose 81 mg aspirin consider contraindication enrollment . Discontinuation prophylactic use antipyretic analgesic medication time enrollment 14 day follow vaccination consider contraindication enrollment . Administration intranasal medication within 14 day prior randomization , expect receipt 14 day study vaccination Nursing mother Employee research center , individual involve conduct study , family member individual Any condition , opinion investigator , would interfere evaluation vaccine interpretation study result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>May 2007</verification_date>
</DOC>